These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11875694)

  • 1. Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.
    Mendes R; O'Brien ME; Mitra A; Norton A; Gregory RK; Padhani AR; Bromelow KV; Winkley AR; Ashley S; Smith IE; Souberbielle BE
    Br J Cancer; 2002 Feb; 86(3):336-41. PubMed ID: 11875694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
    O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
    Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results.
    O'Brien ME; Anderson H; Kaukel E; O'Byrne K; Pawlicki M; Von Pawel J; Reck M;
    Ann Oncol; 2004 Jun; 15(6):906-14. PubMed ID: 15151947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.
    Patel PM; Sim S; O'Donnell DO; Protheroe A; Beirne D; Stanley A; Tourani JM; Khayat D; Hancock B; Vasey P; Dalgleish A; Johnston C; Banks RE; Selby PJ
    Eur J Cancer; 2008 Jan; 44(2):216-23. PubMed ID: 18164612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
    Andreopoulou E; Ross PJ; O'Brien ME; Ford HE; Priest K; Eisen T; Norton A; Ashley S; Smith IE
    Ann Oncol; 2004 Sep; 15(9):1406-12. PubMed ID: 15319247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma.
    Nicholson S; Guile K; John J; Clarke IA; Diffley J; Donnellan P; Michael A; Szlosarek P; Dalgleish AG
    Melanoma Res; 2003 Aug; 13(4):389-93. PubMed ID: 12883365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant mesothelioma--the UK experience.
    O'Brien ME
    Lung Cancer; 2004 Aug; 45 Suppl 1():S133-5. PubMed ID: 15261447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.
    Assersohn L; Souberbielle BE; O'Brien ME; Archer CD; Mendes R; Bass R; Bromelow KV; Palmer RD; Bouilloux E; Kennard DA; Smith IE
    Clin Oncol (R Coll Radiol); 2002 Feb; 14(1):23-7. PubMed ID: 11899903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
    Hunt KJ; Longton G; Williams MA; Livingston RB
    Chest; 1996 May; 109(5):1239-42. PubMed ID: 8625674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
    Middleton GW; Smith IE; O'Brien ME; Norton A; Hickish T; Priest K; Spencer L; Ashley S
    Ann Oncol; 1998 Mar; 9(3):269-73. PubMed ID: 9602260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
    Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
    J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung.
    Stanford JL; Stanford CA; O'Brien ME; Grange JM
    Eur J Cancer; 2008 Jan; 44(2):224-7. PubMed ID: 17928219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
    Fizazi K; Caliandro R; Soulié P; Fandi A; Daniel C; Bedin A; Doubre H; Viala J; Rodier J; Trandafir L; Le Chevalier T; Cvitkovic E; Armand J; Ruffié P
    Eur J Cancer; 2000 Aug; 36(12):1514-21. PubMed ID: 10930799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.
    Sauter ER; Langer C; Coia LR; Goldberg M; Keller SM
    J Surg Oncol; 1995 Oct; 60(2):100-5. PubMed ID: 7564374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
    Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
    J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
    Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
    J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive multimodality therapy for malignant pleural mesothelioma.
    Rice TW; Adelstein DJ; Kirby TJ; Saltarelli MG; Murthy SR; Van Kirk MA; Wiedemann HP; Weick JK
    Ann Thorac Surg; 1994 Jul; 58(1):24-9. PubMed ID: 7518666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.